» Articles » PMID: 18295729

Antiphospholipid Antibodies, Antiphospholipid Syndrome and Infections

Overview
Journal Autoimmun Rev
Publisher Elsevier
Date 2008 Feb 26
PMID 18295729
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Since the association between antiphospholipid antibodies (aPL) and syphilis was first described, many other viral, bacterial and parasitic infections have been shown to induce antiphospholipid antibodies, notably anticardiolipin antibodies (aCL). A review of the literature shows that while aCL occur frequently in viral infections, particularly in HIV (49.75%), HBV (24%) and HCV (20%), it is very rarely associated with anti-beta2 glycoprotein I antibodies (anti-beta2GPI) and is not correlated with thrombosis risk or hematological manifestations of the antiphospholipid syndrome (APS). Concerning bacterial infections, aCL is often present in leprosy (42.7%), where it is frequently associated with the presence of anti-beta2GPI (44.8%), and in syphilis infections (8 to 67%), though without correlation with thrombotic events. Though few individual patients with unequivocal infection-induced aPL satisfy criteria for APS, the lack of statistical association with thrombotic events strongly argues against the identification of a true APS subset in this context. However, physicians should keep in mind the fact that an infection, generally bacterial, in patients with confirmed APS, may lead to catastrophic antiphospholipid syndrome with a possible fatal outcome.

Citing Articles

Antiphospholipid Antibodies as Key Players in Systemic Lupus Erythematosus: The Relationship with Cytokines and Immune Dysregulation.

Richter P, Badescu M, Rezus C, Ouatu A, Dima N, Popescu D Int J Mol Sci. 2024; 25(20).

PMID: 39457063 PMC: 11509045. DOI: 10.3390/ijms252011281.


Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.

Okunlola A, Ajao T, Sabi M, Kolawole O, Eweka O, Karim A Cureus. 2024; 16(9):e69730.

PMID: 39429267 PMC: 11490264. DOI: 10.7759/cureus.69730.


Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?.

Hardy M, Catry E, Pouplard M, Lecompte T, Mullier F Res Pract Thromb Haemost. 2024; 8(6):102536.

PMID: 39290988 PMC: 11406037. DOI: 10.1016/j.rpth.2024.102536.


Challenging in leprosy relapse with antiphospholipid syndrome diagnosis: A case report.

Kolahi S, Ghadakchi L, Sarmadian A, Azimi H, Jafarpour M, Khalaji A Clin Case Rep. 2024; 12(4):e8705.

PMID: 38550732 PMC: 10965750. DOI: 10.1002/ccr3.8705.


Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development.

Muller-Calleja N, Grunz K, Nguyen T, Posma J, Pedrosa D, Meineck M Blood. 2023; 143(12):1167-1180.

PMID: 38142429 PMC: 10972716. DOI: 10.1182/blood.2023022276.